FVC (% predicted) Change from baseline · adults with CFRD
Summary of findings: insulin showed no clear difference in FVC % predicted: change from baseline compared with placebo (low certainty).
1 finding from 1 review
Change in BMI · adults with CFRD
Summary of findings: insulin showed no clear difference in BMI(kg/m²): change from baseline compared with placebo (low certainty).
1 finding from 1 review
Hypoglycemia: number of episodes · adults with CFRD
Summary of findings: insulin showed no clear difference in hypoglycemia: number of episodes compared with placebo (low certainty).
1 finding from 1 review
HbA1c (%) · adults with CFRD and fasting hyperglycemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted · adults with CFRD and fasting hyperglycemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FVC · adults with CFRD and fasting hyperglycemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Body‐mass index (BMI) · adults with CFRD and fasting hyperglycemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hypoglycemia mean number of events per participant · adults with CFRD and fasting hyperglycemia
It is very uncertain whether summary of findings: NPH insulin changes hypoglycemia mean number of events per participant compared with glargine (very low certainty).
1 finding from 1 review
Intervention not reported
Insulin sensitivity · people with stroke or transient ischaemic attack
1 finding from 1 review
Adverse events ‐ Diabetes mellitus requiring insulin · patients with Guillain‐Barré syndrome
Corticosteroid leads to higher adverse events ‐ diabetes mellitus requiring insulin compared with control (high certainty).
1 finding from 1 review
Intervention not reported
Postop insulin sensitivity (clamp) measured as standardized glucose infusion rate (mg/kg/min)l · adult patients undergoing elective surgery
1 finding from 1 review
Intervention not reported
Insulin ‐ hypoglycaemia (< 60 mg/dL) · patients with leading to fewer clinical adverse events
The intervention showed no clear difference in insulin ‐ hypoglycaemia (< 60 mg/dL) (low certainty).
1 finding from 1 review
Intervention not reported
Insulin ‐ severe hypoglycaemia (< 40 mg/dL) · patients with leading to fewer clinical adverse events
It is very uncertain whether the intervention changes insulin ‐ severe hypoglycaemia (< 40 mg/dL) (very low certainty).
1 finding from 1 review
Intervention not reported
Length of stay (days) ‐ insulin · saving healthcare resources
1 finding from 1 review
Intervention not reported
Insulin: time in target glucose range (%) · patients with leading physiological parameters within therapeutic range
1 finding from 1 review
Intervention not reported
Time to achieve therapeutic range ‐ insulin: time to achieve therapeutic control (hours) · patients with reducing time to achieve therapeutic control
1 finding from 1 review
Intervention not reported
All‐cause mortality a. Intervention vs placebo [30 weeks to 4.75 years] b. Intervention vs insulin [4.75 years to 10.0 years] · participants with type 2 diabetes mellitus
The intervention showed no clear difference in all‐cause mortality a. Intervention vs placebo [30 weeks to 4.75… (low certainty).
1 finding from 1 review
Intervention not reported
Cancer a. Intervention vs thiazolidinediones [52 weeks to 4 years] b. Intervention vs insulin [6 years to 10 years] · participants with type 2 diabetes mellitus
The intervention showed no clear difference in cancer a. Intervention vs thiazolidinediones [52 weeks to 4 years]… (low certainty).
1 finding from 1 review
Intervention not reported
Health‐related quality of life a. Intervention vs thiazolidinediones [12 months] b. Intervention vs insulin [6 years] c. Intervention vs alpha‐glucosidase inhibitors [12 months] · participants with type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
Cardiovascular mortality a. Intervention vs placebo [30 weeks to 4.75 years] b. Intervention vs insulin [4.75 years to 10.0 years] · participants with type 2 diabetes mellitus
The intervention may leads to higher cardiovascular mortality a. Intervention vs placebo [30 weeks to… (low certainty).
1 finding from 1 review